Benzodiazepine Use and Hepatitis C Seroconversion in a Cohort of Persons Who Inject Drugs.

• Autores: Paxton Bach, Geoffrey Walton, Kanna Hayashi, M.-J. Milloy, Huiru Dong, Thomas Kerr, Julio S.G. Montaner, Evan Wood
• Localización: American journal of public health, ISSN 0090-0036, Vol. 106, Nº. 6, 2016, págs. 1067-1072
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objectives. To examine the relationship between benzodiazepine (BZD) use and HCV seroconversion in 2 linked prospective cohorts of persons who inject drugs (PWID). Methods. We examined prospective cohorts of 440 PWID (baseline BZD users: n = 102; 23.2%) from the AIDS Care Cohort to Evaluate Access to Survival Services (ACCESS) and the Vancouver Injection Drug Users Study (VIDUS) cohorts, followed-up from 1996 to 2013 in Vancouver, Canada. Results. At baseline, the prevalence of HCV was higher among those who used BZD (80.5% vs 61.5%; P < .001). After adjustment, BZD use remained independently associated with increased rates of HCV seroconversion (adjusted rate ratio = 1.67; 95% confidence interval = 1.05, 2.66). Conclusions. BZD use is independently associated with HCV seroconversion in a population of PWID. [ABSTRACT FROM AUTHOR]